Although this lack of difference may be reasonably attributed to the limited sample size, data presented in our study also demonstrated that authentic and clinically relevant tumor responses and/or long-term stabilization may be achieved with cetuximab-based treatment in patients with KRAS-mutated tumors. The gene discussed is KRAS; the disease is neoplasm.